Company Contact: John F. DeBernardis, Ph.D., President & CEO
Agency Contact: Ira Weingarten/Steve Chizzik
Media Contact: Jeff Siegel, Monarch Communications
(917) 837- 5866
Applied NeuroSolutions Profiled in Chicago Sun-Times
Vernon Hills, IL, August 8, 2005 -
Applied NeuroSolutions, Inc. (OTC BB: APNS, www.appliedneurosolutions.com), a biotechnology company dedicated to developing products to diagnose and treat Alzheimer's disease ("AD"), was recently the subject of a favorable feature article in the Chicago Sun-Times ( http://www.suntimes.com/output/knowles/cst-fin-health01.html), the company said.
The article stressed that there is currently no definitive way to diagnose AD without first ruling out other dementias as well as other neurological disorders, such as Parkinson's, depression and stroke, typically resulting in a time-consuming, costly process.
The article notes the ability of APNS's test to detect AD at a very early stage before major neurological damage has occurred. Current treatments for AD may be more effective if used in patients at this early stage of the illness.
"The Company's test, which is highly sensitive and specific in diagnosing AD in laboratory samples, may also be useful for doctors diagnosing patients with mild cognitive impairment (MCI), to distinguish between those who will ultimately progress to AD and those who are simply suffering memory loss as a part of aging," stated Dr. John DeBernardis, President and CEO of Applied NeuroSolutions.
The article also noted that the company is working on a blood-based test, which "holds even greater revenue potential than the company's CSF (cerebrospinal fluid) test," Dr. DeBernardis added.
"We are very pleased with the increased media interest in APNS," Dr. DeBernardis continued. "As the population continues to age, the media is taking a greater interest in helping to keep people informed about the latest developments in diagnosing and treating AD."
Applied NeuroSolutions, Inc. is developing products to diagnose and treat Alzheimer's disease based on a novel hypothesis of AD pathology. In partnership with Dr. Peter Davies and a scientific team at Albert Einstein College of Medicine, Applied NeuroSolutions has developed a cerebrospinal fluid (CSF) test to detect Alzheimer's disease at a very early stage with 85%-95% accuracy in more than 3,000 patient samples.
The company is also developing a blood serum-based screening test, as well as a new class of therapeutics to treat AD. Alzheimer's disease currently afflicts over 4 million Americans, and the market for AD therapy is expected to grow to 21 million patients by 2010 in the seven major pharmaceutical markets (USA, France, Germany, Italy, Spain, U.K. and Japan) according to BioPortfolio, Ltd.
There are currently no FDA-approved diagnostic tests to detect Alzheimer's disease.
This press release contains forward-looking statements. Applied NeuroSolutions wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the risks associated with new product development and commercialization, clinical trials, intellectual property, regulatory approvals, potential competitive offerings, and access to capital. For further information, please visit the company's website at www.appliedneurosolutions.com, and review the company's filings with the Securities and Exchange Commission.